Anatara Lifesciences Ltd (ASX: ANR)
Health Care · Biotechnology · AU
AU$0.01
-10.00% today · -40.0% 1Y
Anatara Lifesciences Ltd (ASX: ANR) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.98M and employs 7 people.
Over the last twelve months the share price has lost 40.0%, trading between 0.01 and 0.02.
Tweenvest scores Anatara Lifesciences Ltd across four factors: quality 36/100, value 39/100. Its strongest factor is value.
ANR price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.98M
- Revenue (TTM)
- $220.27K
- P/E
- —
- EPS
- -0.00
- Dividend yield
- —
- Beta (5Y)
- 0.65
- 52-week high
- AU$0.02
- 52-week low
- AU$0.01
- Avg volume (3M)
- —
- Shares outstanding
- 315.95M
- Employees
- 7
- Next earnings
- —
About Anatara Lifesciences Ltd
Anatara Lifesciences Ltd is an Australian enterprise focused on researching, developing, and commercializing scientifically-validated therapies for digestive system ailments affecting both humans and animals. Its product portfolio includes Gastrointestinal ReProgramming (GRP), a proprietary blend combining bromelain with other evidence-based ingredients, specifically formulated to target the underlying issues of human gastrointestinal conditions such as irritable bowel syndrome and inflammatory bowel disease. The firm also offers 3FDC, designed to address anxiety, stress, or depression. In the animal health sector, Anatara provides Detach for treating diarrhea in piglets, BONIFF as an enhanced dry feed formulation for weaned piglets, and ANR-pf, a unique additive for poultry drinking water. This company was founded in 2010 and is headquartered in Carlton, Australia.
- ISIN
- AU000000ANR0
- Founded
- 2010
- Listed since
- Oct 15, 2014
- Exchange
- Australian Securities Exchange
- Currency
- AUD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| CASI Pharmaceuticals, Inc.OTCPK: CASI.F | $2.06M | $0.10 | -9.00% |
| Transgene Biotek LimitedBSE: 526139 | $2.04M | Rs2.55 | +3.24% |
| Kairos Pharma, Ltd.NYSEAM: KAPA | $2.04M | $0.60 | -25.79% |
| Oncology Pharma Inc.OTCPK: ONPH | $2.01M | $0.05 | +4.00% |
| Oragenics, Inc.NYSEAM: OGEN | $1.96M | $0.43 | -4.63% |
| BioRestorative Therapies, Inc.NasdaqCM: BRTX | $1.96M | $1.54 | -19.37% |
| Revelation Biosciences, Inc.NasdaqCM: REVB | $1.93M | $0.48 | -36.22% |
| Onconetix, Inc.NasdaqCM: ONCO | $1.89M | $0.48 | -22.77% |
Figures last refreshed Oct 18, 2026.